Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A
A BI-WEEKLY PUBLICATION FROM THE CEDARS-SINAI CHIEF OF STAFF Nov. 12, 2010 Issue | Archived Issues

Protect Your Family and Your Patients with a Flu Shot

Physicians’ family members can receive free influenza vaccinations from 10 a.m. to 1 p.m. Sunday, Nov. 14, on the second floor of the Steven Spielberg Building. You must register by noon on Friday by calling (310) 423-9586. Members of the medical staff may get their free flu shot in Employee Health Services. Appointments and walk-ins are welcome.

» Read more


MEC Update

At its Nov. 1, 2010, meeting, the Medical Executive Committee revised the language in Section 11.3.2 of the Medical Staff Rules and Regulations; approved the search committee’s recommendation of Sarah Kilpatrick, M.D., as OB/Gyn department chair, and formed a nominating committee for medical staff secretary and treasurer.

MEC Morning After Report - November 2010


Meetings and Events

Run for Her
Nov. 14

Ethics Consultation: Harm or Healing 
Nov. 17

Arrhythmia Symposium at the Cedars-Sinai Heart Institute
Dec. 10

» Read more

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

‘Plavix Resistance’ Test Available at Cedars-Sinai

Physicians now have a test at their disposal to determine if their patients have a resistance to the popular anti-platelet drug Plavix®. Cedars-Sinai is one of the few locations offering this test in the nation.

Plavix (clopidogrel) requires activation in the body by an enzyme called CYP2C19. Genetic variations in the enzyme may limit or completely cancel the drug's efficacy.

These inherited genetic variants are frequent, occurring in 55 percent of Asians, 49 percent of African Americans, and 30 percent of Caucasians. The "Plavix Resistance" test identifies whether a patient has this genetic variant, which affects the drug's metabolism.

This test can be ordered in CS-Link™ or through Cedars-Sinai's Department of Pathology and Laboratory Medicine and only requires a 5 mL EDTA purple top tube of blood. The report is available within 10 days.

The "Plavix Resistance" test is the most recent addition to the department’s growing menu of companion diagnostics to promote personalized therapy by helping physicians choose the appropriate drug and dose for patients, said Jean R. Lopategui, M.D., director of Molecular Pathology and Cytogenetics. The department also offers testing for warfarin and irinotecan sensitivity.

In March 2010, the U.S. Food and Drug Administration updated the Plavix package insert with its Black Box warning about poor metabolizers of Plavix and the existence of tests that can identify the genetic differences in patients' CYP2C19 metabolic function. Identification of genetic variations prior to initiation of Plavix therapy may avoid adverse drug reactions such as bleeding and clotting, thus maximizing drug efficacy.

Plavix is primarily indicated for unstable angina, acute coronary syndrome (NSTEMI/STEMI) and post PCI/stent placement.

If you would like more information, please contact Dr. Lopategui at (310) 423-7847 or jean.lopategui@cshs.org.